NCT01488188View on ClinicalTrials.gov

Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Healthy
Interventions
BIOLOGICAL

Influenza vaccine

Administration of 1 dose (0.2 ml) by nasal route

BIOLOGICAL

Influenza vaccine

Administration of 1 dose (0.2 ml) by sublingual route

Trial Locations (1)

110744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

International Vaccine Institute

OTHER

NCT01488188 - Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route | Biotech Hunter | Biotech Hunter